Navigation Links
Hepatitis in Medical Technology

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

PRINCETON, N.J., July 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) reported today positive preliminary results from its phase I clinical trial of PSI-7851 for the treatment of hepatitis C (HCV). PSI-7851 is a second generation nucleotide polymerase inhib...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has successfully completed a three-day...

Clinical Update - Debio 025 in Hepatitis C

LAUSANNE, Switzerland, April 28 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, presented results from a phase IIa study with Debio 025, a selective cyclophilin (...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

Final results from three large PEGINTRON(TM) clinical studies address key questions in the treatment of hepatitis C COPENHAGEN, Denmark, April 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that final results of three large PEGINTRON(TM) (peginterferon ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

- Combination of R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency in reducing viral load in patients with hepatitis C - NUTLEY, N.J., BRISBANE, Calif., and PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Roche, InterMune, Inc. (Nasdaq: IT...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

Start of trial triggers $10 million milestone payment to Pharmasset PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today announced that the first patient has been dosed in a Phase IIb study of R7128, th...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

Data Being Presented Today at 44th Annual Meeting of EASL Management to Discuss Study Results and Program Status During Q1 Financial Results Call at 5 P.M. EDT Today SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced that ANA598,...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

48-week investigational regimen yielded nearly double SVR rate compared to standard of care Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting COPENHAGEN, Denmark, April 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) toda...

ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent

FREDERICK, Md., April 21 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support the development of novel small molecule therapeutics for the treatment of hepatitis C virus (HCV) inf...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

- Company will increase focus on HCV pipeline - Conference call at 8:00 AM ET today PRINCETON, N.J., April 20 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that after a discussion with its independent Data Safety Monitoring Board (DSMB) and the FDA, the co...

Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)

PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that dosing has started in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV)....

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

New use for PEGINTRON(TM) and REBETOL(R) offers certain patients a second chance to achieve treatment success KENILWORTH, N.J., March 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) has approved new label...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable to peginterferon alfa-2a dosed weekly in patients with genotype 1 chronic hepatitis C - - Patients receiving 900-mcg Albuferon had comparable rates o...

Clinical Update - Debio 025 in Hepatitis C

LAUSANNE, Switzerland, January 26 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today the randomisation of its first patient in a phase IIb clinical study with Deb...

Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

CAMBRIDGE, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that it has initiated a proof-of-concept...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

Company reaffirms its innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhi...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: ITMN ) today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV)....

Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008

Nearly 90 percent of patients achieve undetectable viral load in Phase IIa trial within 28 days of combined treatment with standard of care SAN FRANCISCO, Nov. 1 /PRNewswire/ -- New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that a planned...

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients

- Higher Sustained Virological Response Rates Recognized as Marker of Treatment Success - SAN FRANCISCO, Calif., Nov. 1 /PRNewswire/ -- A new, independently-conducted study being presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) shows th...

FDA Approves First Hepatitis B Viral Load Test

Another Roche first in TaqMan(R) real-time PCR testing for the diagnostic lab PLEASANTON, Calif., Sept. 4 /PRNewswire/ -- The U.S. Food & Drug Administration (FDA) has approved the Roche COBAS(R) TaqMan(R) HBV Test, the first assay for quantitating Hepatitis B V...

Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program

- Long term follow up results from chronically infected Hepatitis C patients strongly confirm and exceed positive data obtained earlier in 2008 - Study is the first to show a statistically significant and long-term antiviral effect of therapeutic Hepatitis C vaccination - Data pav...

Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

- 88% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1000mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with Pegasys plus Copegus - PRINCETON, N.J., Aug. 5 /PRNewswir...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

74 percent of patients achieved SVR 12 with 48-week boceprevir-based combination therapy High SVR 24 rate also reported for 28-week boceprevir arm KENILWORTH, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported top-li...

Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus

Study Demonstrates Feasibility and Efficacy of Treating Patients with Primary Liver Cancer SAN FRANCISCO, and YONGIN-SI, South Korea, July 22 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., announ...

Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

96-week comparative study of Clevudine versus Viread(R) versus Clevudine+Viread(R) in 150 patients with chronic hepatitis B PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, In...

InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C

- Fifth cohort of MAD study supports continued development in treatment-experienced patients - BRISBANE, Calif., May 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that it has begun dosing in its Phase 1b clinical trial evaluating ITMN-191...

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

KENILWORTH, N.J., May 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ), a leader in hepatitis research, today announced that it is initiating two large Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, in patients chronically infect...

Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders

TAMPA, Fla., May 21 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biopharmaceutical company, today announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in U.S. pat...

Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C

- IND or foreign regulatory equivalent filing anticipated in 1Q 2009 - PRINCETON, N.J., May 19 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) has nominated PSI-7851 as a lead development candidate for the treatment of chronic hepatitis C virus (HCV). PSI-7851 is a proprietary nuc...

PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C

- Largest prospective study in under-treated and under-studied population (The LATINO Study) provides important insights - SAN DIEGO, Calif., May 18 /PRNewswire/ -- Roche today announced results from the LATINO study, the largest prospective study to evaluate the response of Latino w...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

KENILWORTH, N.J., May 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that data from several clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REB...

Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C

- Two 4-week cohorts will evaluate R7128 1000mg BID in HCV genotype 1 treatment-naive patients and R7128 1500mg BID in HCV genotypes 2 or 3 treatment-experienced patients - PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) has commenced ...

Clinical Update - Debio 025 in Hepatitis C

Presentation of Phase IIa Efficacy Results LAUSANNE, Switzerland, April 28 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions, particularly oncology, presented positive efficacy resu...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

MILAN, Italy, April 26 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that results from a planned interim analysis of an ongoing Phase II study of boceprevir, its investigational oral hepatitis C protease inhibitor, in 595 treatment-naive patients with chronic hepatit...

BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients

MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with BARACLUDE(R) (entecavir) resulted in greater long-term viral l...

Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

- 85% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with Pegasys plus Copegus - - EASL presentation availabl...

Important Progress Toward Control of Hepatitis B and C

Positive Tests Results for New Drugs Against Hepatitis C Improved Screening for Hepatitis C Reflects Physicians' Optimism New Drugs Effective Against Hepatitis B, But Patient Selection Necessary MILAN, April 25 /PRNewswire/ -- Scientists presenting at today's sessions of the 43rd ...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008

Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy and New Insights into Mechanism of Action of Nitazoxanide MILAN, Italy, April 23 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxani...
Other Tags
(Date:7/10/2014)... July 7, 2014 According to ... "Electronic Access Control Systems Market Global Forecast, Market Share, ... global Electronic Access Control systems market was valued at ... grow at a CAGR of 12.6% from 2014 to ... million in 2019. Browse the full Electronic ...
(Date:7/10/2014)... NORTHFIELD, Ill. , July 9, 2014 /PRNewswire-USNewswire/ ... record (EHR), spurred in large part by meaningful ... way health care providers interact with laboratory information. ... well-versed in the field of clinical informatics in ... care. To address the educational needs ...
(Date:7/10/2014)... German . An ... a central step of photosynthesis in action for the first ... State University used the world,s most powerful X-ray flashlight at ... of a molecular complex called photosystem II as it splits ... oxygen in earth,s atmosphere. The researchers report their results in ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4Scientists watch photosynthesis in action 2Scientists watch photosynthesis in action 3
(Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
(Date:7/11/2014)... Re-tearing a repaired knee Anterior Cruciate Ligament (ACL) ... presented today at the American Orthopaedic Society for Sports ... education regarding modifiable risk factors may minimize the chance ... suggests that a few risk factors such as, age, ... to the possibility of re-injury," said lead author, Christopher ...
(Date:7/11/2014)... 11, 2014 With the maturity and ... on comfort, the installation rate of Chinese car electric ... installation rate exceeded 88% and the demand outnumbered 75 ... next few years, Chinese car electric window regulator market ... the market size is expected to exceed 110 million ...
(Date:7/11/2014)... 2014 Wild by Nature, a natural and ... they are opening a fifth store to be located in ... one of the largest selections of wheat and gluten-free products ... disease, these stores have become a one-stop shop for anyone ... sensitivity, and gluten intolerance, is a spectrum of disorders, including ...
(Date:7/11/2014)... July 11, 2014 B. E. Smith, the ... has been retained to lead a national chief nursing ... in Bend, Ore. The top executive search firm ... more than 900 healthcare executives into organizations. , With ... Charles Health System is the largest provider of medical care ...
Breaking Medicine News(10 mins):Health News:ACL Reconstructions May Last Longer With Autografts 2Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 2Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 3Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 4Health News:Wild by Nature Opens New Location 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 3
Other Contents